Aldeyra TherapeuticsALDX +7.57%29 Return-on-Tangible-Equity is -31.97% as of Mar. 2026. GuruFocus rates ALDX with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,201 Biotechnology companies, Aldeyra Therapeutics ranks worse than 56.29% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Aldeyra Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was $-13.81 Mil. Aldeyra Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $43.20 Mil. Therefore, Aldeyra Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -31.97%.
The historical rank and industry rank for Aldeyra Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
ALDX'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -90.31 Med: -60.18 Max: -27.73
Current: -53.76
During the past 13 years, Aldeyra Therapeutics's highest Return-on-Tangible-Equity was -27.73%. The lowest was -90.31%. And the median was -60.18%.
ALDX's Return-on-Tangible-Equity is ranked worse than 56.29% of 1201
companies
in the Biotechnology industry
Industry Median: -42.4
vs ALDX: -53.76
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Aldeyra Therapeutics Return-on-Tangible-Equity Related Terms
Aldeyra Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Aldeyra Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALDX vs ONCY, VRCA, CUE: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Aldeyra Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aldeyra Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Aldeyra Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -31.97% mean?
Aldeyra Therapeutics (ALDX) has a Return-on-Tangible-Equity of -31.97% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Aldeyra Therapeutics and its competitors. According to the industry distribution chart, Aldeyra Therapeutics ranks #676 out of 1201 companies in the Biotechnology industry, placing it in the top 56.3%.
Is Aldeyra Therapeutics' Return-on-Tangible-Equity too high?
Aldeyra Therapeutics' current Return-on-Tangible-Equity is -31.97%. Based on the distribution chart, Aldeyra Therapeutics ranks #676 out of 1201 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' Return-on-Tangible-Equity compare to ONCY and VRCA?
According to the Biotechnology industry distribution chart, Aldeyra Therapeutics ranks #676 out of 1201 companies for Return-on-Tangible-Equity. This places Aldeyra Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Aldeyra Therapeutics and its competitors. Aldeyra Therapeutics's current Return-on-Tangible-Equity is -31.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (ALDX) has a current Return-on-Tangible-Equity of -31.97%. The current Return-on-Tangible-Equity is -31.97%. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current Return-on-Tangible-Equity is -31.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score
Get the complete analysis for ALDX
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALDX has been successfully added to your 
